Emactuzumab (RG7155) is a mAb to CSF-1R that enhances T cell-mediated anti-tumor immune responses via a mechanism of specific inhibition of CSF-1R dimerization and consequent clearance of M2 macrophages expressing the CD163 antigen and CSF-1R [90]. This evidence concerns the gene CD163 and neoplasm.